Sentences with phrase «talimogene laherparepvec»
Imlygic (talimogene laherparepvec), a first - of - its - kind therapy, showed promise against lesions in the skin and lymph nodes in an early trial, the FDA said Tuesday.
http://www.health.com/
Efficacy and safety of talimogene laherparepvec neoadjuvant treatment plus surgery versus surgery alone for melanoma.
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T - VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB - IV melanoma.
Primary overall survival from OPTiM, a randomized phase III trial of talimogene laherparepvec (T - VEC) versus subcutaneous granulocyte - macrophage colony - stimulating factor (GM - CSF) for the treatment of unresected stage IIIB / C and IV melanoma.
In October 2015 — around the same time that the FDA was granting several approvals and indication extensions to checkpoint inhibitors — the agency approved the oncolytic virus (herpes simplex virus 1)-- derived therapy talimogene laherparepvec (T - VEC) for the treatment of melanoma lesions in the skin and lymph nodes.
The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.
Recently, it approved the first intralesional therapy, talimogene laherparepvec (T - VEC), for the treatment of metastatic melanoma lesions in the skin and lymph nodes.
Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T - VEC) in the OPTiM study and the contribution of surgery to response.
A multicenter, open - label trial of talimogene laherparepvec (T - VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB - IV melanoma.
The study consists of two phases and involves two promising immunotherapy drugs: pembrolizumab and talimogene laherparepvec (T - VEC).
The immunotherapy drugs are ipilimumab (Yervoy ®), pembrolizumab (Keytruda ®), nivolumab (Opdivo ®), and talimogene laherparepvec (T - VEC, Imlygic ™).
Called talimogene laherparepvec (Imlygic ™), and made by Amgen, the immunotherapy is an oncolytic virus therapy.
The following year, the FDA approved Amgen's IMLYGIC ™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that recurs after initial surgery.
Our team was instrumental in the development of talimogene laherparepvec, the first in human oncolytic virus therapy for patients with melanoma.
T - VEC, also called talimogene laherparepvec, is a human herpes simplex virus that is genetically engineered to bring T cells into a tumor and induce an antitumor response.